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Abstract: In Italy a specific surveillance system for zoster does not exist, and thus updated 
and complete epidemiological data are lacking. The objective of this study was to 
retrospectively review the national hospital discharge forms database for the period 1999-
2005 using the code ICD9-CM053. In the period 1999-2005, 35,328 hospital admissions 
have been registered with annual means of 4,503 hospitalizations and 543 day-hospital 
admissions. The great part of hospitalizations (61.9%) involved subjects older than   
65 years; the mean duration of stay was 8 days. These data, even if restricted to 
hospitalizations registered at national level, confirm the epidemiological impact of shingles 
and of its complications. 
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1. Introduction 
 
Varicella (chickenpox) is a highly contagious infectious disease caused by an alpha-herpes virus: the 
Varicella Zoster Virus (VZV). From the epidemiological point of view, man is the only reservoir of 
infection and VZV spreads from person to person via droplet nuclei or via direct contact with skin 
OPEN ACCESSInt. J. Environ. Res. Public Health 2009, 6          
 
2345
lesions. The virus has a global distribution and a typical endemic-epidemic course. The infection 
mostly affects childhood and the higher incidence rates are registered in the 0-14 years age class [1]. 
In Italy universal mass vaccination against varicella has not been adopted and, for this reason, VZV 
continues to spread, causing each year a number of cases corresponding to a birth cohort [2]. 
During primary infection, the etiological agent has the ability to infect the sensory nerves in 
mucocutaneous sites and then to become latent in the sensory-nerve ganglia [3]. In detail, after 
replication at the portal of entry there is a viremia and the spreading of the virus to skin and mucosae. 
Afterwards, there is a new replicative phase causing both the typical cutaneous rash and the infection 
of sensory nerves in the epithelium. From the sensory nerves the virus reaches the sensory ganglia were 
it becomes latent. The reactivation of the latent virus, years or decades after primary infection, causes 
the typical clinical expression called Zoster. 
From the immunological point of view, VZV elicits a long-lasting response against the clinical 
expression (varicella or chickenpox); however, naturally acquired immunity neither prevents virus 
latentization nor its possible reactivation. Natural infection stimulates both humoral and cell-mediated 
immunity (CMI) [4]. Nowadays, CMI is considered extremely important, as VZV reactivation is 
believed as strictly related to a decrease of specific T-lymphocytes [5]. An episode of zoster elicits a 
restore of CMI and usually recurrent episodes of shingles are rare. 
During life-time the risk of an episode of zoster is estimated equal to 10-30% and it is strictly  
age-related. Incidence increases sharply with aging; about 50% of subjects aged 80 years or older are 
affected by at least one episode of zoster [6]. 
From the clinical point of view, in the immunocompetent patient zoster is characterized by a 
dermatomal vesicular rash, lasting about 2-3 weeks and accompanied by moderate to severe pain. The 
clinical picture can involve any dermatome, but the preferred sites are the thoracic or lumbar nerve 
segments and the distribution area of the trigeminal nerve. Usually a prodromic phase, lasting a few 
days (1-5), foregoes the clinical expression of the disease; this is characterized by pain, even burning, 
hitch, paraesthesia, etc. In the immunocompetent subject the vesicular phase lasts about one week; 
afterwards, blisters dry out and turn into crusts which fall off after 2-4 weeks [7]. In some patients mild 
forms, even without rash (zoster sine herpete), can occur. An important number of patients experiences 
a long-lasting pain that does not end with the disappearance of the rash but persists for some weeks, 
and even months or years. This chronic neuropathic pain is defined as post-herpetic neuralgia (PHN). 
PHN is an important cause of stress and disability and contributes significantly to the worsening of 
patients’ quality of life [8,9]. PHN is estimated to occur in 10-20% of zoster cases; differences in the 
incidence rate are related to the different definitions of PHN and to the age of patients [10]. As a matter 
of fact, the incidence of PHN increases with age. In immunocompromised patients, particularly in 
those affected by cellular immunodeficiency, zoster can be clinically more severe, with atypical 
presentations, forms with necrosis and involvement of internal organs [11].
 The decay of CMI and 
aging are considered risk factors for the development of zoster. However, even in immunocompetent 
subjects, intrauterine exposure and VZV acquisition before 18 months of age are related to an 
increased risk. Other risk factors, such as gender, seasonality, exposure to immunotoxic chemical 
substances, mechanical traumas and genetic susceptibility have not been clearly related to zoster 
development [6]. Int. J. Environ. Res. Public Health 2009, 6          
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In Italy, a specific surveillance system for zoster does not exist and therefore complete and updated 
epidemiological data are not available at a national level. Notification of zoster cases is usually not 
performed and existing data have been obtained by research performed in different areas and with 
different methodologies. At a national level, there is the possibility to evaluate the hospital discharge 
forms (SDO) which represent an official instrument of the Italian Ministry of Health containing clinical 
and organizational information related to the hospitalizations [12]. The purpose of this study was to 
provide updated epidemiological data, describing the trend of the hospitalizations for zoster in Italy 
through a search in the national SDO database. 
 
2. Methods 
 
2.1. Background 
 
The SDO database was officially established in 1991 [13]; each form is a concise and accurate 
summary of the case history. It allows one to collect in a systematic and economic way the main 
information included in the case history and to check their quality later. Each SDO provides 
information about every patient discharged from all public and private hospitals nationwide and is 
filled in by the doctors who treated the patient. Information regard both clinical (diagnosis, symptoms, 
surgical interventions, diagnostic-therapeutic procedures, prosthetic implantations, methods of 
discharge) and organizational aspects (operative unit of admission and discharge, transfers, who pays 
for admission costs, etc.). The clinical information is coded by the international ICD9-CM system 
(International Classification of Diseases, 9
th revision, Clinical Modification), currently used in Italy 
[14]. The SDO are then coded and transmitted to the Regions and to the National Ministry of Health to 
be included in the regional and national SDO database. 
 
2.2. Study Design 
 
In this research, the national database was retrospectively searched over the period 1999-2005 using 
the code ICD9-CM 053. Noteworthy, in the regional SDO only the main diagnosis is included and 
cases are ordered by solar year and age groups. The search can be performed in the age classes: 0-14 
years, 15-64 years and >64 years; a further subdivision of these groups is not available. Data related to 
each single hospitalization/day hospital admission are not available; for this reason some statistical 
analysis (e.g., comparison between average length of stay, etc.) were not possible. 
In detail, we searched for hospitalizations due to zoster (ICD code 053), herpes zoster with 
meningitis (ICD 0530), herpes zoster with unspecified complications of the nervous system (ICD 
05310), Ramsay Hunt syndrome (ICD 05311), trigeminal post-herpetic neuralgia (ICD 05312), post-
herpetic polyneuropathy (ICD 05313), herpes zoster with other complications of the nervous system 
(ICD 05319), eyelid dermatitis due to herpes zoster (ICD 05320), keratoconjunctivitis due to herpes 
zoster (ICD 05321), uveitis due to herpes zoster (ICD 05322), herpes zoster with other ophtalmic 
complications (ICD 05329), otitis externa due to herpes zoster (ICD 05371), herpes zoster with other 
specified complications (ICD 05379), herpes zoster with unspecified complications (ICD 0538), herpes Int. J. Environ. Res. Public Health 2009, 6          
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zoster without complications (ICD 0539). Statistical analysis was performed by StatView software 
version 5.0; differences among percentages were assessed by the chi-square test. 
 
3. Results 
 
In the period 1999-2005, 35,328 hospitalizations for zoster have been registered in total: 31,526 
hospitalizations and 3,802 day-hospital admissions. The annual mean was equal to 4,503 
hospitalizations and 543 day-hospital admissions; these data correspond to 14 admissions per day. The 
annual incidence of HZ hospitalizations (day hospital admissions included) per 1,000 inhabitants 
ranged between 0.070 and 0.1/1,000 (respectively in 2005 and 1999). 
In the examined period a gradual and significant decrease of hospitalizations was observed (5,383 in 
1999, 3,536 in 2005); however, a significant increase of day-hospital admissions was registered. These 
were 507 in 1999 and 558 in 2005, representing the 8.6% and the 13.6% of hospitalizations due to HZ 
in the same years, respectively (chi square = 117.036; p < 0.01). In the same period, the analysis of 
admissions for any cause showed an analogous, even if more evident, trend; there was a gradual and 
significant decrease of hospitalizations (from 10,165,184 in 1999 to 8,970,561 in 2005) and a 
corresponding increase of day-hospital admissions (2,502,993 in 1999 and 3,984,338 in 2005) (chi  
square = 70822.219; p < 0.01). 
The analysis of SDO data, stratified according to gender, has always shown a greater number of 
cases in females; the 55% of hospitalizations due to herpes zoster in the period 1999-2005 involved 
this gender. Moreover, the predominance of female gender is clear, analyzing the stratification of both 
Italian population (chi square = 322.621; p < 0.0001) and hospitalizations due to any cause (chi square 
= 602.602; p < 0.001) (Table 1). 
Hospitalizations due herpes zoster stratified according to age classes showed an increase with aging; 
in the period 1999-2005, the 61.9% of hospitalizations has involved subjects older than 65 years (26% 
in 65-74 yrs age group and 35.9% in >75 yrs. age group) (Figure 1). 
The average length of hospital stay, evaluated only for hospitalizations, was 8 days. This value 
resulted greater in older patients: 6.8 days and 8.8 days in subjects <65 yrs. and >65 yrs, respectively. 
 
Table 1. Resident population and hospitalizations due to all causes and herpes zoster, Italy 
1999-2005. 
Year Males  Females  Total 
Resident population 
1999 27,563,748 29,345,361 56,909,109 
2000 27,562,988 29,360,536 56,923,524 
2001 27,576,326 29,384,366 56,960,692 
2002 27,587,242 29,406,500 56,993,742 
2003 27,766,223 29,554,847 57,321,070 
2004 28,068,608 29,819,637 57,888,245 
2005 28,376,804 30,085,571 58,462,375 Int. J. Environ. Res. Public Health 2009, 6          
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Table 1. Cont. 
Hospitalizations due to all causes 
1999  5,963.752 6,704,425 12,668,177 
2000  5,870,813 6,679,844 12,550,657 
2001  6,047,742 6,873,203 12,920,945 
2002  6,039,504 6,891,981 12,931,485 
2003  5,989,023 6,814,980 12,804,003 
2004  6,054,139 6,925,270 12,979,409 
2005  6,051,244 6,903,655 12,954,899 
Hospitalizations due to herpes zoster 
1999  2,635 3,255 5,890 
2000  2,522 3,099 5,621 
2001  2,472 3,012 5,484 
2002  2,330 2,879 5,209 
2003  2,163 2,524 4,687 
2004  1,904 2,439 4,343 
2005  1,873 2,221 4,094 
 
 
Figure 1. Herpes zoster: hospitalizations and day-hospital admissions stratified by age 
classes, Italy 1999-2005. 
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Besides, in order to perform a thorough investigation, the different ICD9-CM codes of the different 
subgroups included in the code 053, corresponding to zoster, were considered. The code ICD 0539 
(herpes zoster without complications) included 52% of all hospital admissions due to zoster in the 
observed period; the 60% of these cases involved patients older than 65 years. The remaining 48% of 
cases was equally distributed between the remaining codes, which include zoster complications   
(Figure 2).  
 
Figure 2. Herpes zoster: hospitalizations stratified by ICD9CM code, Italy 1999-2005. 
 
 
 
In detail, ocular complications identified by the codes ICD 05321 (keratoconjunctivitis due to 
zoster), 05322 (uveitis due to zoster), 05329 (herpes zoster with other ocular complications), 
represented the 9.8% of total hospital admissions due to zoster (mean length of stay: 8 days). 
Neurological complications, including the codes ICD9-CM 0530 (herpes zoster with meningitis), 
05310 (herpes zoster with unspecified complications of the nervous system), 05311 (Ramsay Hunt 
syndrome), 05312 (trigeminal post-herpetic neuralgia), 05313 (post-herpetic polyneuropathy), 05319 
(herpes zoster with other nervous system complications), represented the 23.5% of all hospitalizations 
due to zoster in the period 1999-2005. The mean length of stay of these cases was 10 days. The 
remaining 15% of hospital admissions included the following ICD codes: 0538 (herpes zoster with 
unspecified complications), 05320 (eyelid dermatitis due to zoster), 05371 (otitis externa due to zoster), 
05379 (herpes zoster with other specified complications). 
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4. Discussion 
 
The mandatory notification system adopted at national level for infectious diseases includes zoster 
among diseases notifiable in the 5th Class [15]. Many diseases included in this group are erroneously 
considered not subject to notification and, for this reason, adequate and updated epidemiological data 
are missing. This also happens for zoster, and the estimates of the impact of this disease come from 
studies conducted in different areas and with different methodologies. For example, a retrospective 
research performed at national level in 1996 involving dermatologists, geriatric doctors and general 
practitioners provided an estimate that each year in Italy about 200,000 cases of zoster and 42,000 
cases of PHN occur in subjects older than 15 yrs. According to this study, the estimated incidence of 
zoster was equal to 4.14 cases per 1,000 subjects >15 yrs.; the 45.8% of cases were registered in 
subjects older than 65 yrs. (47.1% in subjects >55 yrs.) and the 44.2% of cases involved still working 
subjects. The mean duration of each case was 11-15 days and complications occurred in the 26.1% of 
cases. PHN came out as the most important and frequent complication (26.1%); antiviral therapy was 
prescribed for almost every patient [16]. Another study, performed in the Latium Region, took into 
account direct and indirect costs and estimated the overall costs of a zoster case equal to 987.00 € [17]. 
More recently, an observational prospective research performed in the Piedmont Region evaluated all 
cases of zoster diagnosed by a group of general practitioners. The annual incidence was 1.74 cases per 
1,000 subjects older than 14yrs.; the rate standardized by age in the same group was 1.59 per 1,000 
subjects. The rate of hospital admission was 0.12/1,000 inhabitants. The mean cost of each domiciliary 
case and hospital admission was equal to 136.06 € and 4082.59 €, respectively [18]. 
The data obtained in the present study, even if exclusively related to national hospitalizations, 
confirm the epidemiological impact of zoster and of its complications. This pathology involves all age 
groups; however, as observed in other studies, the disease is more frequent in older subjects [19]. With 
aging, there is an increase of both incidence and mean duration of hospital stay; this one is strictly 
related to the increased co-morbidity typical of older people. The higher incidence rates in the female 
population are related to the fact that old women are numerically prevalent on the old men, as can be 
drawn analyzing the stratification by gender of both the Italian population and the overall hospital 
admissions. 
Considering the different ICD9-CM codes, 50% of cases are identified as herpes zoster without 
complications. The hospital admissions identified as cases with complications were of neurological 
(23.5%) and ocular (9.8%) pertinence. Noteworthy, cases with neurological complications showed a 
longer length of stay (10 days vs 8 days of other admissions). 
The impact of a disease should be evaluated also from an economic perspective. One method for the 
determination of costs related to hospitalizations is the evaluation of Diagnosis Related Groups (DRG) 
rates. According to the DRG reimbursement system, every hospitalized patient belongs to a group of 
cases diagnostically homogeneous; therefore, patients within each category are clinically similar and 
are expected to use the same level of hospital resources. For these reasons, patients in the same DRG 
group are assigned to the same reimbursement charges. In case of outliers (patients with a length of 
stay value higher or lower to that individually established for every DRG), the cost-weight increases or 
decreases for every day more or less compared to the average length of stay. A specific DRG for zoster 
does not exist. According to the great variability of the different DRGs that could be assigned to Int. J. Environ. Res. Public Health 2009, 6          
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hospital admissions for zoster (range 887.32–4740.17 €), it is quite difficult to estimate the economic 
impact of hospitalized cases. 
All these data confirm the great impact of herpes zoster in the population [20]. Besides, treatment 
options for zoster and its complications are often sub-optimal and this fact implies a bad quality of 
patient’s life [21,22]. The new knowledge on zoster etiopathogenesis and the compelling need to 
prevent this disease have prompted researchers to evaluate the possibility to reduce the incidence and 
severity of zoster and of its complications boosting CMI. In the last decade it has been demonstrated 
that varicella vaccines with a high antigenic content could elicit a significant increase of CMI in old 
immunocompetent subjects [23]. A “zoster vaccine”, with a mean potency of 24,600 PFU (an antigenic 
content 14 times greater than the paediatric formulation of varicella vaccine), has been developed. A 
clinical trial performed in subjects >60 yrs of age allowed to demonstrate that this vaccine is safe, well 
tolerated and able to impact on the disease decreasing the burden of the illness (61.1%), the incidence 
of zoster (51.3%) and the incidence of PHN (66.5%) [24].
 The data of this clinical trial showed that a 
“zoster vaccine” can significantly boost CMI and is an interesting opportunity of preventive 
intervention against zoster and its complications [25]. Recently, the Advisory Committee on 
immunization practices (ACIP) has provided recommendations for the use of the already commercially 
available “zoster vaccine” among adults aged ≥60 years in the United States [26]. 
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